相关实验视频

Updated: Jun 23, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

血液恶性瘤中与CAR-T细胞疗法相关的凝血异常:一篇综述

Xiaojuan Peng¹, Xialin Zhang¹, Meiling Zhao¹

¹Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ShanXi, China.

British journal of haematology

|June 18, 2024

概括

化学抗原受体 (CAR) -T细胞疗法可以导致凝血异常,从轻度到严重出血. 本综述详细介绍了这些并发症,以提高在CAR-T细胞治疗期间的患者安全.

科学领域:

血液学血液学血液学
免疫治疗是一种免疫疗法.
在瘤学瘤学.

背景情况:

化学抗原受体 (CAR) -T细胞疗法对复发性/耐药性血液性恶性瘤有效.
显著的进展扩大了CAR-T细胞治疗的临床应用.
凝血异常是常见的并发症,从轻微的参数变化到严重的出血或扩散性血管内凝血 (DIC) 不同.

研究的目的:

为提供与CAR-T细胞治疗相关的凝血异常的全面概述.
突出临床表现,凝血参数,病原和危险因素.
检查这些异常对治疗疗效的影响,并提高患者的安全性.

主要方法:

本综述综合了关于CAR-T细胞治疗和相关凝血障碍的现有文献.
它分析了临床数据,实验室发现和拟议的机制.
重点是描述凝血问题的范围及其临床相关性.

主要成果:

卡特-T细胞治疗与一系列的凝血障碍有关.
这些并发症可以表现为出血,血栓形成或DIC,可能导致多器官功能障碍.
正在确定特定的风险因素和病原遗传途径,尽管数据仍在不断积累.

结论:

凝血异常在CAR-T细胞治疗中是一个重大问题,影响患者的治疗结果.
了解这些并发症对于提高安全性和疗效至关重要.
需要进一步的研究和数据收集来完善管理策略.

关键词:

流血出血流血出血嵌合式抗原受体 (CAR) -T细胞凝血障碍凝血障碍扩散的血管内凝血.血液学恶性瘤血液学恶性瘤血栓形成的原因是血栓形成.

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...